Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

0
32
Syndax Pharmaceuticals announced that the US FDA has granted Priority Review for its New Drug Application (NDA) for revumenib for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
[Syndax Pharmaceuticals]
Press Release